ProQR Therapeutics N.V. (PRQR) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, losing 33.3% versus a loss of 33.5%. Over five years, PRQR leads with a -80.1% price change compared with -94.7% for RNAC. ProQR Therapeutics N.V. is the larger company by market cap ($229.3 million vs $212.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRQR | RNAC |
|---|---|---|
| Share price | $1.63 | $7.03 |
| Market cap | $229.32M | $212.70M |
| 1-day change | +3.49% | +3.08% |
| YTD return | -22.28% | -5.41% |
| 1-year return | -33.47% | -33.33% |
| 5-year return | -80.08% | -94.68% |
| EPS (TTM) | $-0.45 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.10 | $11.00 |
| 52-week low | $1.33 | $5.60 |
| Distance from 52-week high | -47.58% | -36.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +378.77% | +378.95% |
| Average volume | 796.41K | 133.50K |
| Shares outstanding | 141.12M | 30.26M |
| Employees | 186 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
PRQR vs RNAC FAQ
Which is bigger, ProQR Therapeutics N.V. or Cartesian Therapeutics?
ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $229.32M compared with $212.70M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, PRQR or RNAC?
RNAC returned -33.33% over the past 12 months, compared with -33.47% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are ProQR Therapeutics N.V. and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.